(19)
(11) EP 4 114 406 A1

(12)

(43) Date of publication:
11.01.2023 Bulletin 2023/02

(21) Application number: 20889252.1

(22) Date of filing: 21.05.2020
(51) International Patent Classification (IPC): 
A61K 31/70(2006.01)
C07H 19/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61P 31/12; C07H 19/06; C07H 1/00
(86) International application number:
PCT/TR2020/050437
(87) International publication number:
WO 2021/101475 (27.05.2021 Gazette 2021/21)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 21.11.2019 TR 201918165
19.03.2020 TR 202004297

(71) Applicant: Gaziantep Universitesi Rektörlügu
27310 Sahinbey / Gaziantep (TR)

(72) Inventors:
  • TAYSI, Seyithan
    27310 Sehitkamil/Gaziantep (TR)
  • ALI, Omeed Akbar Ali
    27310 Sehitkamil/Gaziantep (TR)
  • AL-GBURI, Firas Shawqi Abdulrazzaq
    27310 Sehitkamil/Gaziantep (TR)

(74) Representative: Handanoglu, Erdal 
Simaj Patent Consulting Limited Mutlukent Mahallesi 1933. Cadde No:8 Çankaya
06810 Ankara
06810 Ankara (TR)

   


(54) SYNTHESIS AND IMPROVEMENT OF A NUCLEOSIDE ANALOGUE AS AN ANTI-CANCER AND ANTI-VIRAL DRUG